Customize your JAMA Network experience by selecting one or more topics from the list below.
Hull RD, Pineo GF, Francis C, et al. Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison. Arch Intern Med. 2000;160(14):2199–2207. doi:10.1001/archinte.160.14.2199
Based on the current understanding that venous thrombosis starts perioperatively, administration of just-in-time low-molecular-weight heparin immediately before or in close proximity after hip arthroplasty may be more effective than usual clinical practice.
We performed a randomized, double-blind trial comparing subcutaneous dalteparin sodium given once daily immediately before or early after surgery with the use of postoperative warfarin sodium in 1472 patients undergoing elective hip arthroplasties. The primary end point was deep vein thrombosis detected using contrast venography performed after surgery (mean, 5.7 days) in each group.
The frequencies of deep vein thrombosis for patients with interpretable venograms receiving preoperative and postoperative dalteparin for all deep vein thrombosis were 36 (10.7%) of 337 (P<.001) and 44 (13.1%) of 336 (P<.001), respectively, vs 81 (24.0%) of 338 for warfarin; for proximal deep vein thrombosis, 3 (0.8%) of 354 (P = .04) and 3 (0.8%) of 358 (P = .03), respectively, vs 11 (3.0%) of 363. Relative risk reductions for the dalteparin groups ranged from 45% to 72%. Symptomatic thrombi were less frequent in the preoperative dalteparin group (5/337 patients [1.5%]) vs the warfarin group (15/338 patients [4.4%]) (P = .02). Serious bleeding was similar among groups. Increased major bleeding at the surgical site was observed for patients receiving preoperative dalteparin vs warfarin (P = .01).
A modified dalteparin regimen in close proximity to surgery resulted in substantive risk reductions for all and proximal deep vein thrombosis, compared with warfarin therapy. Such findings have not been observed with low-molecular-weight heparin therapy commenced 12 hours preoperatively or 12 to 24 hours postoperatively vs oral anticoagulants. Increased major but not serious bleeding occurred in patients receiving preoperative dalteparin. Dalteparin therapy initiated postoperatively provided superior efficacy vs warfarin without significantly increased overt bleeding.
EPIDEMIOLOGICAL data demonstrate that perioperative and postoperative venous thrombosis are common in high-risk patients undergoing surgery.1-5 In the absence of thromboprophylaxis, this disorder occurs in 40% to 60% of patients receiving hip implants.5,6 Prophylactic recommendations against venous thromboembolism in patients undergoing hip arthroplasty include warfarin sodium and subcutaneous low-molecular-weight heparin therapy.5,6
Clinical practice differs in North America and Europe regarding the initiation time of prophylaxis in patients undergoing surgery. Use of low-molecular-weight heparin has been evaluated in patients undergoing hip arthroplasty in multiple level 1 randomized trials.7-29 European practice has largely consisted of commencement of low-molecular-weight heparin therapy 12 hours preoperatively.8-11,13-16,18,21-24,26-29 The European approach recognizes that deep vein thrombosis typically commences perioperatively and that preoperative prophylaxis optimizes antithrombotic effectiveness.30,31 Delayed initiation (12-24 hours postoperatively) of low-molecular-weight heparin prophylaxis is standard practice in North America to minimize bleeding risk.7,12,17,19,20,32 This disparity in clinical practice has led to the expressed need (by the International Consensus Statement) for a level 1 randomized trial evaluating the time of initiation of low-molecular-weight heparin thromboprophylaxis.6 A recent unblinded, randomized trial suggests that low-molecular-weight heparin prophylaxis is superior to warfarin; in this context, both regimens were commenced preoperatively.25
It is possible that low-molecular-weight heparin administered in closer proximity to surgery, in the immediate preoperative or early postoperative period, may be more effective than current clinical practice. This just-in-time concept harmonizes with the current understanding that the risk for thrombosis starts perioperatively.
To date no studies have compared immediate preoperative or early postoperative commencement of low-molecular-weight heparin vs warfarin prophylaxis.33 We performed a double-blind randomized trial evaluating the following 3 differing pharmacological approaches: once-daily subcutaneous dalteparin sodium therapy initiated in the immediate preoperative or early postoperative period, or warfarin administered during the acute hospital stay.
This study was a multicenter, randomized, double-blind clinical trial comparing 3 prophylactic regimens in patients undergoing hip arthroplasty. Regimens consisted of dalteparin sodium (Fragmin; Pharmacia & Upjohn, Stockholm, Sweden) and warfarin sodium (Coumadin; Dupont Pharmaceuticals, Wilmington, Del). Twenty-nine centers in the United States and Canada participated in the trial. The efficacy and safety of these approaches were evaluated during the acute hospital stay (day 0-6 ± 2). A second concurrent study investigated extended out-of-hospital prophylaxis; this is beyond the scope of this article and will be reported separately.
The protocol was approved by each center's institutional review board.
We enrolled consecutive eligible patients aged at least 18 years and scheduled for elective unilateral total hip arthroplasty (primary or revision) who gave informed consent. Patients were eligible if they had none of the following: documented bleeding within 3 months before surgery; known hypersensitivity to heparin, low-molecular-weight heparin, warfarin, or contrast media; defective hemostasis (eg, thrombocytopenia [<100 × 109/L]); ongoing anticoagulants; pregnancy or breastfeeding; clinically significant hepatic dysfunction; renal insufficiency (serum creatinine level, >150 µmol/L [>1.7 mg/dL]); severe hypertension (diastolic blood pressure, >120 mm Hg); septic endocarditis; weight of less than 40 kg; eye, ear, or central nervous system surgery within 1 month before surgery; diseases with unfavorable prognosis (eg, malignant neoplasms or other intercurrent disease making study participation impractical or medically complicated); inability to follow instructions or perform procedures, including self-injections required during the home prophylaxis study; simultaneous participation in another pharmacological study or use of any investigational drug within 30 days before surgery; previous randomization into this study; or use of pneumatic compression stockings.
Of the 5114 patients undergoing screening, 1585 consented to participate. The remaining did not participate because of ongoing anticoagulant use or defective hemostasis (258 patients); diseases with unfavorable prognosis or intercurrent diseases making participation impractical (264 patients); inability to perform procedures (eg, self-injections) required by the study (337 patients); participation declined (1990 patients); previous randomization into the trial (98 patients); or miscellaneous reasons (582 patients).
On the day of surgery, another 84 patients were ineligible due to postponement of surgery (24 patients), miscellaneous reasons (20 patients), and withdrawal of informed consent (40 patients).
Before randomization, the 1501 eligible patients were stratified according to study center. We used a randomized, computer-derived treatment schedule to assign treatment regimens. To obtain continuing balance of treatments, the randomization list was divided into consecutive blocks.
Patients randomized to preoperative dalteparin sodium received their initial 2500-IU subcutaneous injection within 2 hours before surgery (mean ± SD, 49 ± 49 minutes) and only if the spinal procedure was uncomplicated.34 These patients received a second dose of dalteparin sodium, 2500 IU, subcutaneously at least 4 hours postoperatively (mean ± SD, 6.6 ± 2.3 hours). Patients randomized to postoperative dalteparin received a placebo injection immediately before surgery as described above. Their first active dalteparin injection was administered at least 4 hours postoperatively (mean ± SD, 6.6 ± 2.4 hours). On subsequent days, all patients receiving dalteparin sodium were given 5000 IU subcutaneously once daily each morning.
Patients randomized to warfarin received an initial dose postoperatively on the evening of surgery day. The initial dose was 10 mg, except for patients aged 70 years or older or weighing less than 57 kg, who received a 5-mg dose. Thereafter, warfarin doses were adjusted daily using a prescriptive protocol according to the prothrombin international normalized ratio (INR) findings with a predefined warfarin nomogram.35 Warfarin doses were adjusted daily to maintain an INR from 2.0 to 3.0.
Patients randomized to receive warfarin also received subcutaneous placebo injections. Patients randomized to receive dalteparin also received placebo capsules (warfarin and its placebo were encapsulated to maintain blinding). To maintain blinding of each patient's treatment assignment, the prothrombin time results were not recorded in the patient's chart or reported to the health care team.17 The INR results were reported only to an unblinded anticoagulant monitor not involved in assessing outcomes. Daily warfarin dose adjustments or dummy orders (for patients receiving placebo capsules for warfarin) were made by the unblinded anticoagulant monitor according to a prescribed dosage schedule. Thus, the use of placebo capsules and injections and the assignment of an independent anticoagulant monitor to adjust INR values maintained double-blinding throughout the study.
Use of anticoagulants (other than study treatment), aspirin, dipyridamole, ticlopidine hydrochloride, and pneumatic compression devices was prohibited during the study. The use of nonsteroidal anti-inflammatory drugs was strongly discouraged.
All patients were examined daily. Bleeding episodes, perioperative and postoperative blood loss, blood replacement requirements, and platelet levels were documented. Patients in whom overt symptoms and/or signs of deep vein thrombosis or pulmonary embolism developed underwent objective testing. Noninvasive surveillance for deep vein thrombosis was not performed in patients without clinically suspected deep vein thrombosis, because results of such screening are relatively insensitive in this context.36-41
Bilateral ascending radiocontrast venography was mandated by the protocol and was performed on day 6 ± 2 or at the time of discharge from hospital if this occurred earlier. Venography was performed and the results were interpreted as described elsewhere.42,43 Constant intraluminal filling defects in the popliteal, superficial femoral, common femoral, external iliac, or common iliac veins (with or without constant intraluminal filling defects in the deep veins of the calf) were classified as proximal vein thrombosis; those confined to the deep veins of the calf were classified as calf vein thrombosis. Venographic findings were classified as normal if the deep veins of the calf and the proximal deep veins (including the popliteal, superficial femoral, common femoral, external iliac, and common iliac veins) were visualized adequately in both legs.
Venograms were interpreted by the local radiologist and an independent, blinded central reader (R.D.H.). Disagreements between the local radiologist and the central reader were resolved by a second blinded independent central interpretation; this second reading was decisive. The same process occurred in occasional patients with suspected pulmonary embolism who underwent lung scanning or pulmonary angiography.
Bleeding was documented according to a widely used international classification.44,45 Bleeding was classified as major if it was clinically overt and associated with a decrease in hemoglobin level of 20 g/L or more or required transfusion of 2 U of blood or more; if it was intracranial, intraocular, intraspinal or retroperitoneal; or if it occurred into a prosthetic joint. Bleeding was defined as minor if it was clinically overt without meeting the major bleeding criteria and as trivial if it was clearly of no consequence. Wound hematomas that occurred in the absence of clinically overt blood loss were documented, as were associated complications (infection, persistent drainage, wound dehiscence, and prolongation of the hospital stay). Two central committee members not involved in the patient's care independently adjudicated the bleeding data using the international classification44,45; disagreements were resolved by the independent safety monitor (D.B.).
The frequency of major bleeding was also reported by the site investigator. This differed from the centrally adjudicated bleeding rates as the site investigator decided whether the bleeding was clinically important based on clinical judgment. In contrast, the centrally adjudicated bleeding rates were determined only by the information reported in the case report forms using the criteria described above, which were applied to all reports of bleeding independent of the site investigators' clinical judgment.
In a previous study25 where low-molecular-weight heparin was given within 2 hours before surgery and where safety events were reported based on clinical judgment, there was an increased number of transfusions given in the low-molecular-weight heparin group compared with the warfarin group. The reason, however, for the increased transfusions could not be identified by the recorded blood loss or incidence of major bleeding. For this reason, central adjudication of safety events in our trial included all events from the commencement of surgery up to postoperative day 8.
Serious bleeding as defined by Eriksson et al26 is also provided in the results. Serious bleeding is defined to include patients receiving transfusion of more than 5 U of whole blood or concentrates of red blood cells perioperatively, patients receiving transfusion of more than 7 U of whole blood or concentrates of red blood cells anytime after surgery, or patients with total blood loss of more than 3500 mL.26
If patients had clinically suspected venous thrombosis, objective testing with duplex ultrasonography or ascending contrast venography was required. For patients with suspected pulmonary embolism, objective documentation was required using high-probability lung scan, pulmonary angiogram, or autopsy findings. The methods of performing and interpreting the objective tests are reported in detail elsewhere.44,46-48
We estimated that 1500 patients (500 per treatment group) would be required. This was based on deep vein thrombosis rates on day 6 ± 2 of 12% vs 20% for patients receiving preoperative dalteparin vs warfarin, respectively. The sample size required for a detectable treatment difference with a power of 80% at the 5% significance level (2-tailed test) requires at least 354 patients per group. If an inevaluable frequency of 20% is considered, about 442 patients are required for each group.
The uncorrected χ2 was used to compare frequencies of venous thrombosis, bleeding, and death among treatment groups.49 The Fisher exact test was not used, as expected event frequencies exceeded 5 in all cases. Analysis of deviance based on logistic regression was used to evaluate center variability.49 All P values were 2-tailed. Ninety-five percent confidence intervals for the difference between 2 treatment groups in the incidence of venous thrombosis and bleeding complications were calculated with the normal approximation to the binomial distribution.49
Of 1501 consecutive randomized patients, 496, 487, and 489 patients receiving preoperative and postoperative dalteparin and warfarin, respectively, characteristics of the treatment groups were similar on entry (Table 1). Twenty-nine patients were randomized but did not receive study medication; this occurred because of traumatic spinal tap (1, 3, and 3 patients per group, respectively), cancelled operation, (0, 2, and 1 patients, respectively), presence of exclusion criteria (1, 1, and 1 patient, respectively), withdrawn consent (2, 1, and 3 patients, respectively), or miscellaneous reasons making the patient ineligible (4, 2, and 4 patients, respectively).
The proportion of patients undergoing venography and the adequacy of venography are shown in Table 2.
For patients with interpretable venograms, the frequencies of deep vein thrombosis in patients receiving preoperative and postoperative dalteparin and warfarin for all deep vein thrombosis were 36 (10.7%) of 337, 44 (13.1%) of 336, and 81 (24.0%) of 338, respectively (P<.001 for both preoperative and postoperative dalteparin vs warfarin); for proximal deep vein thrombosis, 3 (0.8%) of 354, 3 (0.8%) of 358, and 11 (3.0%) of 363 (P = .04 and P = .03 for preoperative and postoperative dalteparin vs warfarin, respectively). The relative risk reductions for the dalteparin groups compared with the warfarin group ranged from 45% to 72% (Table 2).
Since thrombosis rates in both dalteparin arms were consistent, we pooled results for both arms (Table 2).
Among centers with 30 or more patients (9 centers), rates of deep vein thrombosis in the 3 treatment arms ranged from 0% to 7.1% for proximal deep vein thrombosis, and 4.4% to 44.8% for deep vein thrombosis overall. Analysis of all centers using logistic regression showed no evidence of interaction between treatment and center.
Bleeding complications are shown in Table 3 and Table 4. Increased major bleeding was observed for the preoperative dalteparin group compared with the warfarin group (Table 3) (P = .01).
Major bleeding events documented by the local site investigators were infrequent and similar among groups. Serious bleeding episodes were also infrequent and similar among groups (Table 3).
Minor and trivial bleeding occurred infrequently (Table 3). Wound hematoma rates were similar among groups, and complicated wound hematomas were rare (Table 3).
Mean hemoglobin levels and blood loss were similar among groups (Table 5). The proportion of patients receiving transfusions was significantly higher (Table 5) for the dalteparin groups compared with the warfarin group (P = .001 and P = .002, respectively). Transfusion volumes were similar among groups (Table 5).
The frequency and distribution of thrombocytopenia (platelet count, <100 × 109/L) is shown in Table 5. Most had concomitant blood loss and decreased hemoglobin levels.
No patient had spinal or epidural hematomas or bleeding associated with neurologic defects.
Objectively documented deep vein thrombosis was observed in 161 patients; only 30 (18.6%) of these patients were symptomatic (Table 2). Thrombosis in 27 of these 30 patients was documented using venography; in 3, using duplex ultrasound. Symptomatic thrombi occurred significantly less frequently in the preoperative dalteparin vs warfarin groups (P = .02) (Table 2).
No patient had objectively documented pulmonary embolism.
Warfarin therapy was adjusted to achieve an INR of 2.0 to 3.0; INR results exceeded 2.0 in 86.0% of patients by day 6.
Our findings demonstrate that dalteparin in the immediate preoperative or early postoperative period was more effective than warfarin for preventing deep vein thrombosis in patients undergoing hip arthroplasty. Frequencies of all and proximal deep vein thrombosis were reduced substantially in patients receiving dalteparin; the relative risk reductions for all and proximal deep vein thrombosis associated with preoperative dalteparin vs warfarin were 55% (P<.001) vs 72% (P = .04), respectively; with postoperative dalteparin vs warfarin, 45% (P<.001) vs 72% (P = .03), respectively. The relative risk reduction for the combined dalteparin group vs warfarin was 50% (P<.001) for deep vein thrombosis and 72% (P = .009) for proximal vein thrombosis. Symptomatic thrombi occurred less frequently in the preoperative dalteparin group (5/337 patients [1.5%]) vs the warfarin group (15/338 patients [4.4%]) (P = .02).
Venography was performed early in our trial (mean, 5.7 days), but the rates of all and proximal deep vein thrombosis observed in the warfarin group were similar to those observed by means of venography performed in patients undergoing hip arthroplasty on days 7 through 14.17,21,25,50
The all and proximal deep vein thrombosis rates for the dalteparin groups were reduced markedly compared with the warfarin group and likely reflect the initiation of dalteparin therapy in close proximity to surgery. Warfarin and low-molecular-weight heparin thromboprophylaxis are recommended by the 1998 American College of Chest Physicians Consensus Conference for patients undergoing elective hip surgery.5 Warfarin traditionally has been used; however low-molecular-weight heparin regimens are assuming increasing predominance. At the time of our clinical trial program implementation, warfarin was the dominant prophylactic approach used in North America. The use of a delayed prophylaxis regimen of low-molecular-weight heparin was not standard clinical practice.
In North America, low-molecular-weight heparin prophylaxis in patients undergoing hip arthroplasty is usually delayed postoperatively for at least 12 to 24 hours to minimize bleeding.7,12,17,19,20 Despite high-risk doses or a twice-daily regimen, these regimens have not shown significant reductions in all or proximal deep vein thrombosis rates compared with warfarin or unfractionated heparin prophylaxis in patients undergoing hip arthroplasty.7,12,17,19,20
We administered low-molecular-weight heparin postoperatively in close proximity to surgery (mean ± SD, 6.6 ± 2.4 hours). To minimize bleeding, the initial postoperative dalteparin sodium dose was only half the high-risk dose (2500 IU); the usual high-risk dose (5000 IU subcutaneously) was resumed the next day. We found that postoperative dalteparin administered early in close proximity to surgery was more effective than warfarin, without a significant increase in major bleeding. This finding is in contrast to studies using 12- to 24-hour postoperative low-molecular-weight heparin regimens that have failed to demonstrate significant risk reductions against oral anticoagulants,17,21 while providing supportive evidence of the superiority of the close proximity strategy.
Dalteparin administered in close proximity to surgery also resulted in unusually low proximal deep vein thrombosis rates compared with those found in European randomized trials that initiated low-molecular-weight heparin therapy 12 hours preoperatively in patients undergoing hip arthroplasty.8-11,13-16,18,21-24,26-29 Low-molecular-weight heparin therapy commenced the evening before hip implant surgery was compared with acenocoumarol therapy commenced the day before surgery in an open-label randomized trial in Europe21; results of venographic evaluation showed similar proximal and all deep vein thrombosis rates (6.5% vs 5.8%, respectively, and 16.5% vs 19.5%, respectively). Dalteparin therapy commenced 2 hours preoperatively in an open-label hip implant study was significantly more effective than warfarin therapy commenced the evening before surgery.25 These findings suggest that our thromboprophylaxis approach in close proximity to surgery is more effective.
Recently, hirudin administered immediately before hip arthroplasty surgery was compared with low-molecular-weight heparin therapy commenced 12 hours preoperatively.26 The just-in-time thrombin-inhibitor regimen was more effective, and serious bleeding episodes were infrequent; these observations are also consistent with our findings.
Major bleeding at the operative site was significantly more frequent in patients receiving preoperative dalteparin vs warfarin using central adjudication (Table 3 and Table 4). The centrally adjudicated major bleeding rate in the warfarin group on days 0 through 1 was 4.1%. Since the first warfarin dose was not administered until the night after surgery, this bleeding rate largely reflected usual bleeding associated with surgery. The central adjudicators lacked the clinical perspective at the bedside and may have overestimated major bleeding from the case report forms because of the difficulty of discriminating between usual operative bleeding and increased bleeding for the perioperative and immediate postoperative interval. Major bleeding reported by site investigators based on clinical judgment using the same criteria as the central adjudicators was low and similar among groups. Serious bleeding episodes as defined by Eriksson et al26 were infrequent and similar among groups. No deaths occurred among patients with major blood loss.
The frequency of major bleeding postoperatively is similar to that reported in the cited literature for patients receiving postoperative low-molecular-weight heparin or warfarin prophylaxis after hip-arthroplasty surgery in North America.12,17,19 The frequency of minor and trivial bleeding was low and similar among groups. Uncomplicated wound hematoma rates were similar among the groups. Complicated wound hematomas occurred infrequently. Blood transfusions were significantly more frequent in the dalteparin groups (Table 5).
Our findings cannot be attributed to bias; randomization was successful because the baseline characteristics of the patients were comparable among groups and the study was conducted in double-blind fashion to avoid bias in searching for or interpreting outcome events. Our findings cannot be attributed to inadequate administration of warfarin, as most patients (86.0%) underwent adequate anticoagulation by day 6. The proportion of patients undergoing evaluation, of those eligible, is comparable to that of other rigorous randomized trials evaluating pharmacological interventions. The frequencies of symptomatic venous thromboembolism were inevitably low as a result of case finding by means of venography, leading to early treatment of deep vein thrombosis.
The proportion of patients with adequate venograms was high (86.6% for proximal visualization of those who underwent venography) and can be attributed to education and feedback provided to participating radiologists throughout the course of the study. Another high-quality double-blind trial reported venogram adequacy rates similar to ours.26
Recently in the United States, concern has arisen about the associated use of neuraxial anesthesia and low-molecular-weight heparin prophylaxis because of a reported cluster of spinal hematomas.51-53 A twice-daily low-molecular-weight heparin regimen has prevailed in the United States, whereas a once-daily regimen has prevailed in Europe; the latter has not been associated with a reported cluster of spinal hematomas. This intercontinental difference may reflect the dominant regimens used.
Our findings indicate that a once-daily low-molecular-weight heparin regimen is sufficient. The once-a-day postoperative regimen has the advantages that accumulation is less likely, that it is effective, and that the postoperative bleeding rates are low. Since half of the usual high-risk dose of dalteparin is given the day of surgery, and the average time of initiation of therapy after spinal anesthesia was 9 hours, the modified postoperative regimen of once-daily dalteparin reported herein may be a safe approach in avoiding spinal hematoma. The cost-effectiveness of in-hospital prophylaxis is beyond the scope of this article and should be addressed separately.
Low-molecular-weight heparin prophylaxis administered preoperatively or postoperatively using a modified dalteparin regimen in close proximity to hip arthroplasty resulted in substantive risk reductions for all and proximal deep vein thrombosis compared with warfarin. Such findings have not been observed with low-molecular-weight heparin therapy commenced 12 hours preoperatively or 12 to 24 hours postoperatively. Major44,45 but not serious26 bleeding occurred more frequently in patients receiving dalteparin in the immediate preoperative period. Dalteparin therapy initiated postoperatively provided superior efficacy vs warfarin, without significantly increased overt bleeding.
Accepted for publication November 4, 1999.
Support for this trial was provided through a grant-in-aid by Pharmacia & Upjohn to the University of Calgary.
The following is a list of the additional coauthors: David Rosenbloom, PharmD, Orthopedic & Arthritic Hospital, Toronto, Ontario; Peter Hanson, MD, Groosmont Hospital and Saddleback Medical Research, San Diego, Calif; Frank Smith, MB ChB, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario; Linda Vickars, MD, St Paul's Hospital, Vancouver, British Columbia; David Green, MD, PhD, Northwestern University, Chicago, Ill; Frank Ariosta, MD, Staten Island University Hospital, Staten Island, NY; William Fisher, MD, Royal Victorian Hospital, Montreal, Quebec; David Ayers, MD, State University of New York Health Science Center at Syracuse; Terence Sparling, MD, Burnaby Hospital Regional Cancer Center, Burnaby, British Columbia; Louis Desjardins, MD, Centre Hospitalier de l'Université Laval, Ste Foy, Quebec; Robert Lavender, MD, University of Arkansas for Medical Sciences, Little Rock; John McCutchen, MD, South Eastern Clinical Research Consultants, Maitland, Florida; Bernard Stulberg, MD, Cleveland Center for Joint Reconstruction, Cleveland, Ohio; William Allen, MD, Pharmacotherapy Research Associates, Zanesville, Ohio; Scott Berkowitz, MD, Duke University Medical Center, Durham, NC; Robert Lerner, MD, New York Medical College, Valhalla; Clifford Colwell, MD, Scripps Clinic, La Jolla, Calif; and Melvin Tonkon, MD, Anaheim Heart & Research Institute, Anaheim, Calif.
A list of additional participants of the North American Fragmin Trial appear below. Special thanks go to Gary Raskob, PhD, of the Clinical Epidemiology Unit, University of Oklahoma Health Sciences Center, Oklahoma City.
University of Alberta Hospital, Edmonton: L. Boshkov, P. Donahue, V. Jordan, M. MacDonald, D. Russell; Peter Lougheed Center and Calgary General Hospital, Calgary, Alberta: J. Dear, D. McKeage, J. Walsh; Foothills Medical Center, Calgary: J. Gardner, J. Lemaire, M. McDonald; Orthopedic & Arthritic Hospital, Toronto, Ontario: M. Ford, C. Bakuska, J. Clark; University of Rochester Medical Center, Rochester, NY: A. Boyd, J. Brennan, E. DeMara, K. Kaplan, V. Marder, A. Rapoport; Grossmont Hospital and Saddleback Medical Research, San Diego, Calif: J. Graydon, B. Hazer, P. Kuey, T. Sheen; Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario: N. Marchetti, L. A. Reynolds, D. Rosenbloom; St Paul's Hospital, Vancouver, British Columbia: P. Galbraith, D. Michaels; Northwestern University, Chicago, Ill: M. Arron, R. Tulabya; Staten Island University Hospital, Staten Island, NY: A. Cernaianu, F. Huie; Royal Victoria Hospital, Montreal, Quebec: R. Brassard, A. Brox, C. Shustik, J. Sinclair, G. Sprull; State University of New York Health Science Center at Syracuse: D. Murray, M.Van Glynn; Southern Illinois University School of Medicine, Springfield: G. Allan, C. Bears, G. Caronis, J. Galles, K. Olin, B. Werries; Burnaby Hospital Regional Cancer Center, Burnaby, British Columbia: W. Leong, E. Scofield; Centre Hospitalier de l'Université Laval, Ste Foy, Quebec: N. Fortier, L. St Pierre; Johns Hopkins University, Baltimore, Md: M. Mont, D. Lennox, D. Hungerford, L. Jones; University of Arkansas for Medical Sciences, Little Rock: C. Harness, T. Holcomb, C. Nelson; South Eastern Clinical Research Consultants, Maitland, Florida: J. Byrnes, J. Simmons; St Joseph's Hospital, Brantford, Ontario: C. Whately, J. Collingwood, L. Dimmel; Northwest Physicians Research Unit, Missoula, Mont: D. McGee, H. Elzinga, M. Kreeger; The Damluji Research Center, San Diego: M. Skyhar, G. Dennish, K. Harden; Cleveland Center for Joint Reconstruction, Cleveland, Ohio: G. Swope, A. Tahir; Pharmacotherapy Research Association, Zanesville, Ohio: K. Crist, M. Crist, C. Cunningham; Health Sciences Center, St Johns, Newfoundland: L. Whitman, S. Murphy, J. Watson; Duke University Medical Center, Durham, NC: T. L. Ortel, D. D. Smith, T. P. Vail, A. C. Womack; New York Medical College, Valhalla: J. Nelson, E. Scorcia; Scripps Clinic, La Jolla, Calif: M. Hardwick, B. Morris, R. Sarnoff; Anaheim Heart & Research Institute, Anaheim, Calif: T. Katzman, V. McKinnon, D. Simons; LDS Hospital, Salt Lake City, Utah: G. Elliott, N. Kitterman, S. Yeates; Uppsala University, Uppsala, Sweden: D. Bergqvist (safety monitor); Pharmacia & Upjohn, Stockholm, Sweden, Kalamazoo, Mich, Toronto, Ontario: C. Björk, P. Carrothers, L. Pan, J. Svensson, C. Taylor; Thrombosis Research Unit, University of Calgary, Calgary: S. Boyle, M. Butcher, C. Lerede, M. McDonald, A. Powell, J. Sheldon, V. Stagg, J. White, C. Wrona.
Reprints: Russell D. Hull, MBBS, MSc, Thrombosis Research Unit, 601 S Tower, Foothills Hospital, 1403-29 St NW, Calgary, Alberta, Canada T2N 2T9 (e-mail: http://www.ucalgary.ca/UofC/faculties/medicine/TRU).
Create a personal account or sign in to: